Bio-Rad Laboratories (BIO) AI Stock Analysis

• Market Cap: $8.14B
• Dividend Yield: N/A
• Average Volume (3M): 169.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: -0.88%
• EPS Growth: 10.93%
• Country: US
• Employees: 7,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.26
• Shares Outstanding: 21,906,399
• 10 Day Avg. Volume: 181,978
• 30 Day Avg. Volume: 169,202
• PEG Ratio: -0.03
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 3.61
• P/FCF Ratio: 34.82
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 2.94
• Enterprise Value/Gross Profit: 5.63
• Enterprise Value/Ebitda: -12.11
• 1Y Price Target: $357.50
• Price Target Upside: 18.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 10.15
• Revenue Forecast (FY): $2.59B

• Rating: 54 Neutral
• Price Target: $315.00 ▲(4.47% Upside)

Bio-Rad Laboratories faces significant financial challenges, with declining profitability and mixed cash flow performance being the most impactful factors. Technical analysis suggests a potential bearish trend, while valuation metrics are unattractive due to negative earnings. The earnings call provided some positive insights, but overall, the stock's outlook remains cautious.

Positive Factors

Process Chromatography Growth

The strong growth in process chromatography indicates robust demand and a competitive edge in this segment, supporting long-term revenue potential.

Droplet Digital PCR Strategy

Advancements in the Droplet Digital PCR strategy enhance Bio-Rad's product offerings and market position, fostering sustainable growth and innovation.

Operating Margin Improvement

Improved operating margins reflect effective cost management, enhancing profitability and financial health over the medium to long term.

Negative Factors

Decline in Life Science Segment

The decline in the Life Science segment suggests challenges in key markets, potentially hindering growth and affecting overall revenue stability.

Gross Margin Decline

Decreasing gross margins due to higher material costs may pressure profitability, affecting long-term financial performance and competitiveness.

Free Cash Flow Decrease

Reduced free cash flow indicates potential liquidity challenges, impacting the company's ability to invest in growth and manage financial obligations.

Bio-Rad Laboratories Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

How the Company Makes Money

Bio-Rad makes money primarily through the sale of its products and services in the life science and clinical diagnostics markets. The company generates revenue through multiple streams, including the sale of laboratory instruments, reagents, consumables, and software solutions. Key revenue streams include instrument sales, which provide significant margins, and recurring revenues from consumables and reagent sales. Additionally, Bio-Rad has established significant partnerships and collaborations with academic institutions, biotech firms, and healthcare providers, enhancing its market presence and driving sales. The company also invests in research and development to innovate and expand its product offerings, which contributes to its long-term revenue growth.

Bio-Rad Laboratories Financial Statement Overview

Summary

Bio-Rad Laboratories is facing financial challenges with declining revenue and profitability. The income statement shows negative net profit margins and operational inefficiencies. The balance sheet is stable with low leverage, but negative ROE is concerning. Cash flow generation is mixed, with a need for improvement in free cash flow.

Income Statement

Bio-Rad Laboratories has experienced a challenging period with declining revenue and profitability. The TTM data shows a revenue growth rate of 12.8%, but the net profit margin is negative, indicating losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Historical data shows a downward trend in revenue and profitability, with significant losses in recent years.

Balance Sheet

The company's balance sheet shows a relatively low debt-to-equity ratio, indicating conservative leverage. However, the return on equity is negative, reflecting the company's inability to generate profits from its equity base. The equity ratio is strong, suggesting a solid capital structure, but the negative ROE is a concern.

Cash Flow

Cash flow analysis reveals a mixed picture. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to reported losses. However, free cash flow growth has been negative in the TTM period, and the free cash flow to net income ratio is moderate. The company needs to improve its cash flow generation to support operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.56B	2.57B	2.67B	2.80B	2.92B	2.55B
Gross Profit	1.34B	1.38B	1.43B	1.57B	1.64B	1.44B
EBITDA	-621.30M	-2.14B	-654.80M	-4.49B	5.59B	5.08B
Net Income	-675.90M	-1.84B	-637.32M	-3.63B	4.25B	3.81B
Balance Sheet
Total Assets	9.70B	9.36B	12.30B	13.50B	17.80B	12.97B
Cash, Cash Equivalents and Short-Term Investments	1.42B	1.66B	1.61B	1.79B	869.92M	991.12M
Total Debt	1.40B	1.37B	1.41B	1.39B	223.38M	225.74M
Total Liabilities	2.96B	2.79B	3.56B	3.89B	4.11B	3.09B
Stockholders Equity	6.74B	6.57B	8.74B	9.62B	13.69B	9.88B
Cash Flow
Free Cash Flow	336.75M	266.20M	218.26M	80.29M	535.72M	476.41M
Operating Cash Flow	491.45M	455.20M	374.94M	194.45M	669.46M	584.97M
Investing Cash Flow	-186.04M	-160.20M	20.21M	-1.21B	-797.38M	-69.89M
Financing Cash Flow	-312.75M	-218.80M	-425.65M	973.58M	-55.43M	-523.04M

Bio-Rad Laboratories Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 301.53
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Neutral. The current price of 301.53 is below the 20-day moving average (MA) of 314.39, below the 50-day MA of 314.82, and above the 200-day MA of 270.98, indicating a neutral trend. The MACD of -3.31 indicates Positive momentum. The RSI at 40.75 is Neutral, neither overbought nor oversold. The STOCH value of 15.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIO.

Bio-Rad Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	80 Outperform	$126.45B	26.64	9.81%	2.76%	5.34%	13.15%
BSX	79 Outperform	$141.74B	51.14	12.66%	―	21.62%	54.80%
DXCM	79 Outperform	$25.76B	36.77	30.63%	―	14.21%	5.66%
EW	79 Outperform	$49.71B	36.47	13.59%	―	0.19%	65.58%
BIO	54 Neutral	$8.14B	-12.41	-9.50%	―	-0.88%	10.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHG	50 Neutral	$25.44B	-32.66	―	3.32%	-0.76%	-55.03%

Bio-Rad Laboratories Corporate Events

Bio-Rad Reports Q3 2025 Financial Results Amid Challenges

On October 29, 2025, Bio-Rad Laboratories reported its financial results for the third quarter ended September 30, 2025. Despite challenges in academic research and biotech funding, the company achieved a slight increase in revenue to $653.0 million, up 0.5% from the previous year. However, a change in the fair market value of its investment in Sartorius AG led to a significant net loss of $341.9 million. The company maintained its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of 0 to 1.0 percent.

Bio-Rad Laboratories Mourns Loss of Co-Founder Alice Schwartz

On September 29, 2025, Bio-Rad Laboratories announced the passing of its co-founder and Director Emeritus, Alice N. Schwartz, on September 25, 2025, at the age of 99. Alice Schwartz, who co-founded the company in 1952, played a pivotal role in its growth and success, particularly in the development of Bio-Rad’s first test kit for thyroid function, which marked the company’s entry into clinical diagnostics. Her leadership and passion for scientific discovery have left a lasting legacy at Bio-Rad and in the broader scientific community.